Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort
Some of the data in this paper were presented at the 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, Oct. 4-7, 2007.
Received 15 September 2007; received in revised form 20 December 2007; accepted 21 March 2008. published online 20 May 2008.
Objective
The objective of the study was to determine the effect of hepatitis C virus (HCV) on selected maternal and infant birth outcomes.
Study Design
This population-based cohort study using Washington state birth records from 2003 to 2005 compared a cohort of pregnant women identified as HCV positive from birth certificate data (n = 506) to randomly selected HCV-negative mothers (n = 2022) and drug-using HCV-negative mothers (n = 1439).
Results
Infants of HCV-positive mothers were more likely to be low birthweight (odds ratio [OR], 2.17; 95% confidence interval [CI] 1.24, 3.80), to be small for gestational age (OR, 1.46; 95% CI, 1.00, 2.13), to need assisted ventilation (OR, 2.37; 95% CI, 1.46, 3.85), and to require neonatal intensive car unit (NICU) admission (OR, 2.91; 95% CI, 1.86, 4.55). HCV-positive mothers with excess weight gain also had a greater risk of gestational diabetes (OR, 2.51; 95% CI, 1.04, 6.03). Compared with the drug-using cohort, NICU admission and the need for assisted ventilation remained associated with HCV.
Conclusion
HCV-positive pregnant women appear to be at risk for adverse neonatal and maternal outcomes.
1Department of Medicine, University of Washington School of Medicine, Seattle, WA
2Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA
3Department of Epidemiology, University of Washington School of Medicine, Seattle, WA.
Reprints: Steven A Pergam, MD, Fred Hutchinson Cancer Center, 1100 Fairview Ave. North, D3-100, P.O. Box 19024, Seattle, WA 98109.
Cite this article as: Pergam SA, Wang CC, Gardella CM, et al. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. Am J Obstet Gynecol 2008;199:38.e1-38.e9.
This study was supported by National Institute of Allergy and Infectious Diseases Grants T32 AI007044 (to S.A.P.) and AI-30731 (to C.M.G.); National Institutes of Health Grant T32 AI007140 (to W.T.P. and T.G.S.); and National Institutes of Health Grant 5 K23 AI51523 (to C.C.W.). Drs Wang and Gardella are members of the speaker's bureau for Roche and GlaxoSmithKline laboratories, respectively. Roche markets a test for hepatitis C, and GlaxoSmithKline is developing a drug intended for use in a treatment program for hepatitis C. Neither company contributed to the design, execution, review, or funding of this study.
ABSTRACT
Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort